Gets By With A Little Help From His Friends Ghost Writers On The High Planes

Thank you Huff Politics

Chuck Grassley Tries To Trick Obama Judicial Nominee Into Criticizing Another Nominee 

Posted: 09/11/2013 2:55 pm EDT  |  Updated: 09/12/2013 1:08 pm EDT 

WASHINGTON -- Sen. Chuck Grassley (R-Iowa) tried to get D.C. Circuit court nominee Robert Wilkins to criticize statements made by another of President Barack Obama's D.C. Circuit nominees, Nina Pillard, during a Senate Judiciary Committee hearing on Wednesday. It didn't work, though.

Senator Chuck Grassley's "judicial philosophy?" 

Say As Please Only When It Benefits You No Matter Who It Harms

Ghost Writers On High Planes

Words That Kill

How About the Facts Jack? 

[Senator Iowa] Grassley has put a spotlight on relationships between drug makers and academia (not to mention drug-makers and doctors, drug makers and medical societies, drug makers and [fill in the blank] ...). In this case, Grassley claims that Wagner, director of child and adolescent psychiatry at UT Medical Branch in Galveston, got more than $160,000 from Glaxo Smith Kline over five years, and she only reported $600 to the university. Over the same period, she was working on a big study of Glaxo's antidepressant Paxil--a study that later caught plenty of flak for allegedly accentuating the positive and downplaying risks of suicidal thoughts and behavior

Read more:
http://www.fiercepharma.com/story/hhs-probes-researchers-ties-drugmakers/2009-05-11?utm_medium=nl&utm_source=internal#ixzz0Y7isJhX3


Senate Finance Committee, sent a letter to the University of Texas System in September raising concerns that child pharmacology researcher Karen Wagner had not properly disclosed her financial connections with drug companies. He reported her in a letter to the Health and Human Services Office of the Inspector General on Tuesday, one addressed to UT System Chancellor Francisco Cigarroa.

An influential U.S. senator has reported a University of Texas researcher's financial relationship with a drug company to the top investigator at the U.S. Department of Health and Human Services.

http://trailblazersblog.dallasnews.com/archives/2009/05/federal-investigator-could-rev.html


Posted by Dr. Callan @ 5:05 PM Fri, May 15, 2009 
http://laikaspoetnik.wordpress.com/2009/05/08/mercks-ghostwriters-haunted-papers-and-fake-elsevier-journals/
This address is for those doubters. Merck set up a phony medical journal to provide biased so-called research to support the toxic pharmaceuticals without peer review. Insider plants like Wagner are the name of the game with big bucks being at stake, the payoffs are hidden in her misstatements, follow the hidden money. She probably hides facts in the research as well.

Gupta Downplayed the Risks of Vioxx
http://www.counterpunch.com/navarro02092009.html

Then there's Vioxx, Merck's disgraced, canceled drug pulled off the market in 2004 after an increased risk of heart disease surfaced among users. There were thousands of lawsuits (settled for just under $5 billion), which faulted Merck for hiding dangers of the drug. But Gupta told Miles O'Brien on CNN's American Morning on October 30, 2003: 

"Miles O'Brien: Let's talk about Vioxx. Some indication it might increase the risk of heart attack? 

"Gupta: This stat has been around since August of 2001. They talked about the increase of heart attack with Vioxx. The numbers are very small. Perhaps a small percentage increase in the overall risk of heart attacks with Vioxx. They say 37 percent to 39 percent but that's of a very small number. After 90 days, no increased risk." 

Bizarre words from Gupta, who later told reporters that he got that information from Merck, the drug's maker

In addition, the Obama administration has decided that the head of the USPHS will play a leading role on the task force in charge of reforming the nation’s health care. 

The person chosen by President Obama to fill this position is Dr. Sanjay Gupta, a neurosurgeon at Emory Medical School in Atlanta and chief 
And, according to Physicians for a National Health Program, in 2003 he downplayed the concerns of the medical community about Vioxx, which was removed from the market a year later by its manufacturer, Merck. 

Read more:
http://cc.bingj.com/cache.aspx?q=dr+sanjay+gupta+vioxx&d=5037880717410760&mkt=en-US&setlang=en-US&w=b411fd11,20bbb7f6#ixzz0Y7Y30PM5